Zanubrutinib appears in the EHA 2026 CLL entity pool as a BTK inhibitor paired with…
Browsing: Life Science
Want to get ideas and solutions for your R&D in Life Science? Check out the resources powered by Patsnap Eureka, find the technical resources you need.
Sonrotoclax is included from high-impact EHA 2026 CLL oral content as a BCL2 inhibitor used…
Allo-RevCAR01-T is part of the RevSTAR-123 switchable allogeneic CAR-T approach in CD123-positive AML, presented as…
R-TM123 is highlighted in the EHA 2026 Late-Breaking Abstract Session. R-TM123 is the targeting module…
LB2501 is the drug or project name, not the abstract number. At EHA 2026, it…
Blinatumomab is included in the EHA 2026 entity workbook as a cd19 x cd3 bispecific…
Mitapivat is highlighted in the EHA 2026 Plenary Abstract Session through S102 RISE UP, evaluating…
Tafasitamab is highlighted in the EHA 2026 Plenary Abstract Session through S101 frontMIND, evaluating tafasitamab…
Pomalidomide is included in the EHA 2026 entity workbook as an immunomodulatory imide drug (IMiD)…
Daratumumab is included in the EHA 2026 entity workbook as an anti-CD38 monoclonal antibody relevant…